Cargando…
ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration
Breast cancer (BRCA) has traditionally been considered as having poor immunogenicity and is characterized by relatively low tumor mutational burden (TMB). Improving immunogenicity may improve the response to clinical immunotherapy of BRCA. However, the relationship between TMB, immune infiltration,...
Autores principales: | Wang, Jia, Zhang, Xiaolu, Li, Jie, Ma, Xiaoran, Feng, Fubin, Liu, Lijuan, Wu, Jibiao, Sun, Changgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835009/ https://www.ncbi.nlm.nih.gov/pubmed/33234738 http://dx.doi.org/10.18632/aging.104204 |
Ejemplares similares
-
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021) -
Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Zhang, Yubao, et al.
Publicado: (2021) -
Deciphering of Key Pharmacological Pathways of Poria Cocos Intervention in Breast Cancer Based on Integrated Pharmacological Method
por: Ma, Xiaoran, et al.
Publicado: (2020) -
Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
por: Ma, Xiaoran, et al.
Publicado: (2022) -
Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
por: Gao, Chundi, et al.
Publicado: (2020)